Adalimumab ‘safe and effective’ in paediatric ulcerative colitis
​​​​​​​The findings come from the largest trial yet evaluating a biologic therapy in children with the disease, researchers say
Adalimumab provides clinically meaningful rates of remission and response in children with moderate-to-severe ulcerative colitis, clinical trial results show.
Overall, 37% of children on the medication had a positive response.
The phase 3 ENVISION I trial is the largest trial yet of a biologic in such children and led to US FDA approval for adalimumab for the indication in February.
The international trial enrolled 93 children (aged 4-17) across 10 countries between 2014 and 2018.
